Chronic kidney disease Trials in Łódź, Poland
Conditions / Chronic kidney disease / Łódź, Poland
Chronic kidney disease has been the subject of sustained clinical investigation across multiple research sites.
33 total trials for this combination
Showing top 10 of 33 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02160145 | Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease | COMPLETED | PHASE3 |
| NCT04595370 | Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease | COMPLETED | PHASE2 |
| NCT02540993 | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease | COMPLETED | PHASE3 |
| NCT05021835 | ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06131372 | A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | COMPLETED | PHASE2 |
| NCT05196035 | A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | RECRUITING | — |
| NCT05457283 | A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria | RECRUITING | — |
| NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT07241390 | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | RECRUITING | — |
| NCT03036150 | A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease | COMPLETED | PHASE3 |